Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines for Cancer

Generex Biotechnology together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, and RXi Pharmaceuticals Corporation announced that they have obtained positive early research data from their collaboration to explore the use of RXi's RNAi technology to develop proprietary vaccine formulations for active immunotherapy

WORCESTER, MA, USA | January 6, 2011 | Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board:GNBT.ob - News), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (www.antigenexpress.com), and RXi Pharmaceuticals Corporation (www.rxipharma.com) (NasdaqCM: RXII), a recognized leader in RNAi-based therapeutics, today announced that they have obtained positive early research data from their collaboration to explore the use of RXi's RNAi technology to develop proprietary vaccine formulations for active immunotherapy.

Initial results from the collaboration demonstrated success in using RXi's proprietary self-delivering rxRNA™ (sd-rxRNA™) compounds to silence genes up to 80% in hemopoietic cells. The ability to knock down expression of certain genes in isolated hemopoietic-derived cancer cells (ex vivo) has the potential to convert them into specific immune-stimulants and opens the possibility for development of a new class of anticancer therapeutic vaccines. RXi's sd-rxRNA compounds may be particularly suitable for this use, since they are able to cross cell membranes without the assistance of any delivery agent.

"We are very pleased to have identified a technology that enables efficient RNAi silencing in hemopoietic cells," said Dr. Eric von Hofe, President of Antigen Express. "These types of cells are notoriously difficult to deliver RNAi and other oligonucleotide molecules to. In contrast to other gene silencing technologies, RXi's compounds act more like small molecules, which may greatly facilitate clinical development."

Antigen Express is developing proprietary vaccine formulations for active immunotherapy and has previously employed a DNA vector approach for silencing expression of the MHC class II-associated invariant chain (Ii protein) in patients with acute myelogenous leukemia. This strategy has been shown to transform cancer cells into specific and potent immunotherapeutic agents to combat cancer in a variety of pre-clinical models. In addition to hematological malignancies, this strategy is applicable to different types of solid tumors as well, such as colon cancer.

"We are pleased to have generated early compelling data in collaboration with Antigen Express for active immunotherapy with potential oncology applications," said Dmitry Samarsky, Ph.D., Vice President of Technology Development at RXi. "Our rxRNA™ therapeutic platform may have exciting applications in the development of therapeutic vaccines, and we look forward to the potential for expanding and further developing this opportunity based on our combined approaches."

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation is a recognized leader in RNAi-based therapeutic discovery and development with a comprehensive therapeutic platform that includes both RNA interference (RNAi) compounds and delivery methods. RXi's sd-rxRNA compounds were developed by our team of world-class scientists, are designed specifically for therapeutic use, and contain many of the properties that are needed to advance RNAi based drugs into the clinic (high potency, reduced immune response activation, novel intellectual property, etc). The Company is leveraging this broad and integrated RNAi therapeutic platform to build a pipeline of RNAi therapeutics for the treatment of a number of disease areas, including its core focus of developing treatments for dermal anti-scarring and retinal disorders as well as a continued interest in oncology and indications accessible by spinal cord delivery. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi therapeutics market based on the strength of its next generation therapeutic platform, experienced management team, accomplished Scientific Advisory Board, including Nobel Laureate, Dr. Craig Mello, and its broad intellectual property position in RNAi chemistry and delivery. www.rxipharma.com

SOURCE: Generex Biotechnology Corporation

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top